Search Result

Results for "

SU 11248-d10

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Antibiotic (1) Apoptosis (12) Autophagy (8) Bacterial (2) Biochemical Assay Reagents (1) c-Kit (6) c-Met/HGFR (3) Caspase (1) CDK (1) Cytochrome P450 (3) Dihydroorotate Dehydrogenase (1) Drug Metabolite (4) EGFR (4) Endogenous Metabolite (3) Eukaryotic Initiation Factor (eIF) (1) FAK (1) FGFR (5) FLT3 (1) Fluorescent Dye (1) Histone Methyltransferase (2) Insulin Receptor (1) Interleukin Related (1) IRE1 (4) Isotope-Labeled Compounds (4) JNK (1) Mitochondrial Metabolism (1) Mitophagy (4) Monocarboxylate Transporter (1) mTOR (2) Na+/K+ ATPase (1) PDGFR (19) PI3K (3) PROTACs (1) Src (1) Tyrosinase (1) VEGFR (23) YB-1 (1)
By Research Areas:	Cancer (53) Cardiovascular Disease (2) Endocrinology (2) Infection (2) Inflammation/Immunology (7) Metabolic Disease (3) Neurological Disease (2)

By Targets:

Akt (2)

Antibiotic (1)

Apoptosis (12)

Autophagy (8)

Bacterial (2)

Biochemical Assay Reagents (1)

c-Kit (6)

c-Met/HGFR (3)

Caspase (1)

CDK (1)

Cytochrome P450 (3)

Dihydroorotate Dehydrogenase (1)

Drug Metabolite (4)

EGFR (4)

Endogenous Metabolite (3)

Eukaryotic Initiation Factor (eIF) (1)

FAK (1)

FGFR (5)

FLT3 (1)

Fluorescent Dye (1)

Histone Methyltransferase (2)

Insulin Receptor (1)

Interleukin Related (1)

IRE1 (4)

Isotope-Labeled Compounds (4)

JNK (1)

Mitochondrial Metabolism (1)

Mitophagy (4)

Monocarboxylate Transporter (1)

mTOR (2)

Na+/K+ ATPase (1)

PDGFR (19)

PI3K (3)

PROTACs (1)

Src (1)

Tyrosinase (1)

VEGFR (23)

YB-1 (1)

By Research Areas:

Cancer (53)

Cardiovascular Disease (2)

Endocrinology (2)

Infection (2)

Inflammation/Immunology (7)

Metabolic Disease (3)

Neurological Disease (2)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153227

SU 5616

c-Met/HGFR Cancer

SU 5616 is an organic compound. SU 5616 potentially modulates tyrosine kinase signal transduction, and regulates abnormal cell proliferation .

SU 5616	c-Met/HGFR	Cancer
SU 5616 is an organic compound. SU 5616 potentially modulates tyrosine kinase signal transduction, and regulates abnormal cell proliferation .

HY-21290

SU-4942	Tyrosinase	Cancer
SU-4942 is a tyrosine kinase signal signal modulator. SU-4942 inhibits VEGF- and endothelial cell growth factor (ECGF)-induced mitogenesis in endothelial cells (US5792783A) .

HY-150231

SU056	YB-1	Cancer
SU056 is a YB-1 inhibitor. SU056 induces cell-cycle arrest, apoptosis, and inhibits cell migration in ovarian cancer cells. SU056 interacts with YB-1 and inhibits and its associated downstream proteins and pathways. SU056 can enhance the cytotoxic effects of Paclitaxel (HY-B0015) .

HY-21292

SU5214

SU4949
VEGFR Cancer

SU5214 is a potent VEGFR2 inhibitor extracted from patent US5834504A, SU5214, has IC₅₀s of 14.8 µM (FLK-1) and 36.7 µM (EGFR), respectively .

SU5214 SU4949	VEGFR	Cancer
SU5214 is a potent VEGFR2 inhibitor extracted from patent US5834504A, SU5214, has IC₅₀s of 14.8 µM (FLK-1) and 36.7 µM (EGFR), respectively .

HY-10407G

SU 5402	VEGFR EGFR PDGFR	Cancer
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively .

HY-100349

SU4312	PDGFR VEGFR	Cancer
SU4312 is the racemate of (Z)-SU4312 and (E)-SU4312. (Z)-SU4312 inhibits PDGFR and FLK-1 with IC₅₀s of 19.4 and 0.8 μM, respectively. (E)-SU4312 inhibits PDGFR, FLK-1, EGFR, HER-2, and IGF-1R with IC₅₀s of 24.2, 5.2, 18.5, 16.9 and 10.0 μM, respectively .

HY-112452

SU11652	VEGFR FGFR PDGFR c-Kit Apoptosis	Cancer
SU11652 is a potent receptor tyrosine kinase (RTK) inhibitor. SU11652 also inhibits several members of the split kinase family of RTKs, including VEGFR, FGFR, PDGFR, and Kit. SU11652 can be uesd for spontaneous cancers expressing Kit mutations research .

HY-118203

SU4984	FGFR PDGFR Insulin Receptor	Cancer
SU4984 is a protein tyrosine kinase inhibitor, with an IC₅₀ of 10-20 μM for fibroblast growth factor receptor 1 (FGFR1). SU4984 is also inhibits platelet-derived growth factor receptor, and insulin receptor. SU4984 can be used for the research of cancer .

HY-B0789

SU6656 10+ Cited Publications	Src FAK Akt	Cancer
SU6656 is a Src family kinases inhibitor with IC₅₀s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.

HY-139056

SU0268 1 Publications Verification	Others	Infection Inflammation/Immunology Cancer
SU0268 is a potent and specific inhibitor of 8-Oxoguanine DNA glycosylase 1 (OGG1). SU0268 regulates inflammatory responses during Pseudomonas aeruginosa infection .

HY-116643

SU 10603

Cytochrome P450 Metabolic Disease

SU 10603 is a specific inhibitor of P45017α (P450c17; CYP17A1) .

SU 10603	Cytochrome P450	Metabolic Disease
SU 10603 is a specific inhibitor of P45017α (P450c17; CYP17A1) .

HY-12014

SU11274 5+ Cited Publications PKI-SU11274	c-Met/HGFR Autophagy Apoptosis	Cancer
SU11274 is a selective Met inhibitor with IC₅₀ of 10 nM, but has no effects on PGDFRβ, EGFR or Tie2.

HY-10407

SU 5402 5+ Cited Publications	VEGFR FGFR PDGFR	Cancer
SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively.

HY-21293

SU5201

Interleukin Related Inflammation/Immunology

SU5201 is an inhibitor of interleukin-2 (IL-2) production .

SU5201	Interleukin Related	Inflammation/Immunology
SU5201 is an inhibitor of interleukin-2 (IL-2) production .

HY-19326

SU1498 5 Publications Verification AG 1498; Tyrphostin SU 1498	VEGFR	Inflammation/Immunology Cancer
SU1498 (AG 1498) is a selective inhibitor of the VEGFR2; inhibits Flk-1 with an IC₅₀ of value of 700 nM .

HY-21289

SU5205

VEGFR Cancer

SU5205 is an inhibitor of VEGFR2 (FLK-1), with an IC₅₀ of 9.6 μM .
HY-136209

SU5208

VEGFR Cancer

SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2) .

SU5205	VEGFR	Cancer
SU5205 is an inhibitor of VEGFR2 (FLK-1), with an IC₅₀ of 9.6 μM .

SU5208	VEGFR	Cancer
SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2) .

HY-10873

N-Desethyl Sunitinib 5 Publications Verification SU-12662	Drug Metabolite	Cancer
N-Desethyl Sunitinib (SU-12662) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor with K_i values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively .

HY-138813

N-Desethyl Sunitinib hydrochloride 5 Publications Verification SU-12662 hydrochloride	Drug Metabolite	Cancer
N-Desethyl Sunitinib (SU-12662) (hydrochloride) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor with K_i values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively .

HY-12013

PD153035 Hydrochloride 5+ Cited Publications SU-5271 Hydrochloride; AG1517 Hydrochloride; ZM 252868 Hydrochloride	EGFR	Cancer
PD153035 Hydrochloride (SU-5271 Hydrochloride) is a potent EGFR inhibitor with K_i and IC₅₀ of 6 and 25 pM, respectively.

HY-10374

Semaxinib

35+ Cited Publications

SU5416
VEGFR Cancer

Semaxinib (SU5416) is a potent and selective inhibitor of VEGFR (Flk-1/KDR) with an IC₅₀ of 1.23 μM .

Semaxinib 35+ Cited Publications SU5416	VEGFR	Cancer
Semaxinib (SU5416) is a potent and selective inhibitor of VEGFR (Flk-1/KDR) with an IC₅₀ of 1.23 μM .

HY-10501

SU14813 1 Publications Verification	PDGFR VEGFR c-Kit	Cancer
SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.

HY-10501A

SU14813 maleate 1 Publications Verification	PDGFR VEGFR c-Kit	Cancer
SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.

HY-18629

SU9516 4 Publications Verification	CDK Autophagy Apoptosis	Cancer
SU9516 is a potent CDK2 inhibitor, with an IC₅₀ of 22 nM, and also shows inhibitory effects on CDK1 and CDK4, with IC₅₀s of 40, 200 nM, respectively.

HY-126319

SU5204

VEGFR EGFR Cancer

SU5204, a tyrosine kinase inhibitor, has IC₅₀s of 4 and 51.5 μM for FLK-1 (VEGFR-2) and HER2, respectively .

SU5204	VEGFR EGFR	Cancer
SU5204, a tyrosine kinase inhibitor, has IC₅₀s of 4 and 51.5 μM for FLK-1 (VEGFR-2) and HER2, respectively .

HY-108628

SU16f 1 Publications Verification	PDGFR	Cancer
SU16f is a potent and selective PDGFRβ inhibitor with IC₅₀s of 10 nM, 140 nM, 2.29 μM for PDGFRβ, PDGFR1, PDGFR2, respectively . Neutralization of PDGFRβ receptor by SU16f blocks the promoting role of GC-MSCs (gastric cancer-derived mesenchymal stem cells) conditioned medium in gastric cancer cell proliferation and migration .

HY-14346

PD153035 5+ Cited Publications SU-5271; AG1517; ZM 252868	EGFR	Cancer
PD153035 (SU-5271; AG1517; ZM 252868) is a potent EGFR inhibitor with K_i and IC₅₀ of 6 and 25 pM, respectively.

HY-10255A

Sunitinib Maximum Cited Publications 47 Publications Verification SU 11248	VEGFR PDGFR IRE1 Mitophagy Autophagy Apoptosis	Cancer
Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .

HY-N4115

Syrosingopine 3 Publications Verification SU 3118	Monocarboxylate Transporter	Cardiovascular Disease Cancer
Syrosingopine (Su 3118) is an orally active lactate transporters (MCT1/MCT4) dual inhibitor, which can reduce glycolysis and induce synthetic lethality in cancer cells when combine with metformin. Syrosingopine shows anti-hypertensive activity by depleting peripheral stores of norepinephrine .

HY-B1232

Metyrapone 5 Publications Verification SU-4885	Endogenous Metabolite Cytochrome P450 Autophagy	Neurological Disease Metabolic Disease Endocrinology Cancer
Metyrapone (Su-4885) is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone can be used for researching Cushing's syndrome and depression .

HY-10330

Toceranib SU11654; PHA 291639E	PDGFR VEGFR c-Kit	Cancer
Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors .

HY-10330A

Toceranib phosphate SU11654 phosphate; PHA 291639E phosphate	PDGFR VEGFR c-Kit	Cancer
Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors .

HY-10255

Sunitinib Malate Maximum Cited Publications 47 Publications Verification SU 11248 Malate	PDGFR VEGFR IRE1 Mitophagy Autophagy Apoptosis	Cancer
Sunitinib Malate (SU 11248 Malate) is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib Malate, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .

HY-18952A

(Z)-SU5614	FLT3 Apoptosis	Cancer
(Z)-SU5614 is a potent FLT3 inhibitor and selectively induces growth arrest, apoptosis, and cell cycle arrest in Ba/F3 and AML cell lines expressing a constitutively activated FLT3 .

HY-N9981

5β-Hydroxybufotalin	Biochemical Assay Reagents	Cancer
5β-Hydroxybufotalin (compound 6) is an anticancer agent that can effectively inhibit the growth activity of cancer cells. 5β-Hydroxybufotalin is also a natural product obtained from the chinese traditional drug Ch'an Su .

HY-103002

SU5408 3 Publications Verification VEGFR2 Kinase Inhibitor I	VEGFR	Cardiovascular Disease
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent and cell-permeable inhibitor of VEGFR2 kinase with an IC₅₀ of 70 nM.

HY-10873S1

N-Desethyl Sunitinib-d4 TFA SU-12662-d<SUb>4SUb> TFA	Drug Metabolite Isotope-Labeled Compounds	Cancer
N-Desethyl Sunitinib-d₄ (SU-12662-d₄) TFA is deuterium-labeled N-Desethyl Sunitinib (HY-10873) .

HY-B1232A

Metyrapone Tartrate SU-4885 Tartrate	Endogenous Metabolite Cytochrome P450 Autophagy mTOR	Neurological Disease Endocrinology
Metyrapone (Su-4885) Tartrate is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone Tartrate inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone Tartrate increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone Tartrate can be used for researching Cushing's syndrome and depression .

HY-W127716

Ru(bpy)2(mcbpy-O-Su-ester)(PF6)2	Fluorescent Dye	Cancer
Ru(bpy)2(mcbpy-O-Su-ester)(PF6)2 is a potent ruthenium-based dye. Ru(bpy)2(mcbpy-O-Su-ester)(PF6)2 can bu used as an effective quencher of quantum dots (QDs) fluorescence and the capture probe of virus antigen EV71. Ru(bpy)2(mcbpy-O-Su-ester)(PF6)2 can be used sensitive electrogenerated chemiluminescence (ECL) labels for detection of matrix metalloproteinases (MMPs) .

HY-107597

Halicin 1 Publications Verification SU3327	JNK	Metabolic Disease Inflammation/Immunology
Halicin (SU3327) is a potent, selective and substrate-competitive JNK inhibitor with an IC₅₀ of 0.7 μM. Halicin also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC₅₀ of 239 nM. Halicin shows less active against p38α and Akt kinase .

HY-10517

Orantinib 3 Publications Verification SU6668; TSU-68	PDGFR FGFR VEGFR Apoptosis	Cancer
Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with K_is of 2.1 μM, 8 nM and 1.2 μM for Flt-1, PDGFRβ and FGFR1, respectively.

HY-119757

Tyrphostin AG1433 SU1433; AG1433	PDGFR VEGFR	Cancer
Tyrphostin AG1433 (SU1433) is a tyrosine kinases inhibitor. AG1433 is also a selective PDGFRβ and VEGFR-2 (Flk-1/KDR) inhibitor with IC₅₀s of 5.0 μM and 9.3 μM, respectively. Tyrphostin AG1433 prevents blood vessel formation .

HY-10517A

(Z)-Orantinib (Z)-SU6668; (Z)-TSU-68	VEGFR PDGFR FGFR	Cancer
(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC₅₀s of 2.1, 0.008, and 1.2 µM, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors .

HY-N2019

Chaetocin 4 Publications Verification	Histone Methyltransferase Bacterial Antibiotic	Infection Cancer
Chaetocin is a specific inhibitor of the histone methyltransferase (HMT) SU(VAR)3-9 with an IC₅₀ of 0.6 μM for SU(VAR)3-9. It also inhibits thioredoxin reductase (TrxR) with an IC₅₀ of 4 μM.

HY-12929

NSC756093 SU093	Others	Cancer
NSC756093 is a potent inhibitor of the GBP1:PIM1 interaction. NSC756093 can potentially revert resistance to paclitaxel. NSC756093 can be used for ovarian cancer research .

HY-N9358

Argentinogenin

Others Cancer

Argentinogenin is a natural compound with anti-cancer activity that could be found in traditional Chinese agent Chan Su .

Argentinogenin	Others	Cancer
Argentinogenin is a natural compound with anti-cancer activity that could be found in traditional Chinese agent Chan Su .

HY-10332

(Z)-Semaxanib (Z)-SU5416	c-Met/HGFR	Cancer
(Z)-Semaxanib (compound (z)-1) is a potent tyrosine kinase inhibitor. (Z)-Semaxanib shows cytotoxicity for TAMH and HepG2 cells with IC₅₀s of 6.28 µM and 8.17 µM, respectively .

HY-10873S

N-Desethyl Sunitinib-d5	Isotope-Labeled Compounds Drug Metabolite	Cancer
N-Desethyl Sunitinib-d₅ is the deuterium labeled N-Desethyl Sunitinib. N-Desethyl Sunitinib (SU-12662) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor with Ki values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively[1].

HY-10330S

Toceranib-d8	Isotope-Labeled Compounds PDGFR VEGFR c-Kit	Cancer
Toceranib-d₈ is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib (SU11654) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors[1][2].

HY-B0083

Leflunomide 5+ Cited Publications HWA486; RS-34821; SU101	Dihydroorotate Dehydrogenase Endogenous Metabolite Bacterial	Cancer
Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1232

Metyrapone 5 Publications Verification SU-4885	Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Cancer	Endogenous Metabolite Cytochrome P450 Autophagy
Metyrapone (Su-4885) is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone can be used for researching Cushing's syndrome and depression .

HY-N2019

Chaetocin 4 Publications Verification	Infection Alkaloids Structural Classification Microorganisms Classification of Application Fields Source classification Disease Research Fields Alkaloid Dimers	Histone Methyltransferase Bacterial Antibiotic
Chaetocin is a specific inhibitor of the histone methyltransferase (HMT) SU(VAR)3-9 with an IC₅₀ of 0.6 μM for SU(VAR)3-9. It also inhibits thioredoxin reductase (TrxR) with an IC₅₀ of 4 μM.

HY-N9981

5β-Hydroxybufotalin	Structural Classification Natural Products Source classification Crassulaceae Echeveria laui Moran et J. Meyrán Plants	Biochemical Assay Reagents
5β-Hydroxybufotalin (compound 6) is an anticancer agent that can effectively inhibit the growth activity of cancer cells. 5β-Hydroxybufotalin is also a natural product obtained from the chinese traditional drug Ch'an Su .

HY-B1232A

Metyrapone Tartrate SU-4885 Tartrate	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Endocrinology	Endogenous Metabolite Cytochrome P450 Autophagy mTOR
Metyrapone (Su-4885) Tartrate is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone Tartrate inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone Tartrate increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone Tartrate can be used for researching Cushing's syndrome and depression .

HY-N9358

Argentinogenin	Structural Classification Classification of Application Fields Animals Source classification Disease Research Fields Steroids Cancer	Others
Argentinogenin is a natural compound with anti-cancer activity that could be found in traditional Chinese agent Chan Su .

HY-B0083

Leflunomide Maximum Cited Publications 7 Publications Verification HWA486; RS-34821; SU101	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Dihydroorotate Dehydrogenase Endogenous Metabolite Bacterial
Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.

HY-N0877

Bufalin 5+ Cited Publications	Structural Classification Classification of Application Fields Animals Source classification Disease Research Fields Steroids Cancer	Na+/K+ ATPase
Bufalin is an active component isolated from Chan Su, acts as a potent Na ⁺/K ⁺-ATPase inhibitor, binds to the subunit α1, α2 and α3, with K_d of 42.5, 45 and 40 nM, respectively . Anti-cancer activity .

HY-N5136

25(R,S)-Ruscogenin	Liliaceae Microorganisms Classification of Application Fields Source classification Liriope platyphylla Wang et Tang Plants Disease Research Fields Steroids Cancer	Apoptosis PI3K Akt mTOR
Ruscogenin suppresses HCC metastasis by reducing the expression of MMP-2, MMP-9, uPA, VEGF and HIF-1α via regulating the PI3K/Akt/mTOR signaling pathway . And Ruscogenin alleviates LPS-induced pulmonary endothelial cell apoptosis by su

Cat. No.	Product Name	Chemical Structure

HY-10873S

N-Desethyl Sunitinib-d5
N-Desethyl Sunitinib-d₅ is the deuterium labeled N-Desethyl Sunitinib. N-Desethyl Sunitinib (SU-12662) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor with Ki values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively[1].

HY-10255AS

Sunitinib-d10
Sunitinib-d₁₀ is a deuterium labeled Sunitinib. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].

HY-10873S1

N-Desethyl Sunitinib-d4 TFA

N-Desethyl Sunitinib-d₄ (SU-12662-d₄) TFA is deuterium-labeled N-Desethyl Sunitinib (HY-10873) .

HY-10330S

Toceranib-d8
Toceranib-d₈ is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib (SU11654) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors[1][2].

HY-10255AS1

Sunitinib-d4
Sunitinib-d₄ is the deuterium labeled Sunitinib. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks